Literature DB >> 2642449

Initial therapy and relapse of duodenal ulcer: possible acid secretory mechanisms.

S G Chiverton1, R H Hunt.   

Abstract

Review of the four studies investigating the effect of initial therapy on ulcer relapse indicates that there is an increased rate of relapse after treatment with H2-receptor antagonists compared with placebo or other classes of drugs when combined. When individual drugs are considered, this appears to hold true for colloidal bismuth alone. There are several possible reasons for these differences. The most likely candidate mechanism to account for these differences is an alteration in gastric secretion, which might arise from alterations in gastrin, altered receptor regulation, parietal cell sensitivity, or peptic activity. However, the evidence for such an alteration in secretion is far from conclusive. Other factors that may be important include mucosal defense factors, smoking, Campylobacter pylori, and the statistical methodology.

Entities:  

Mesh:

Year:  1989        PMID: 2642449     DOI: 10.1016/s0016-5085(89)80059-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

Review 1.  Helicobacter pylori and peptic ulcers: the present position.

Authors:  S Moss; J Calam
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

2.  Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation.

Authors:  M J Collen; M J Sheridan
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

Review 3.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 4.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

5.  Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates.

Authors:  G J Mantzaris; A Hatzis; G Tamvakologos; K Petraki; C Spiliades; G Triadaphyllou
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.